Molecular structure of BMS-345541, CAS Number: 445430-58-0
BMS-345541 (CAS 445430-58-0)
See product citations (1)
Alternate Names:
IKK Inhibitor III
Application:
BMS-345541 is a cell-permeable quinoxaline agent and a potent, selective, and allosteric site-binding inhibitor of IKK β
CAS Number:
445430-58-0
Purity:
≥96%
Molecular Weight:
483.4
Molecular Formula:
C14H17N5•2C2HF3O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
BMS-345541 is a cell-permeable quinoxaline compound that shows anti-inflammatory properties. BMS-345541 is a potent, selective, and allosteric site-binding inhibitor of IKK-2. Displays ~10-fold greater selectivity over IKK-1 and no activity towards IKKε and a panel of more than 15 unrelated protein kinases even at concentrations as high as 100 μM. Inhibits cellular IκBα phosphorylation.
BMS-345541 (CAS 445430-58-0) References
- BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. | Burke, JR., et al. 2003. J Biol Chem. 278: 1450-6. PMID: 12403772
- A selective IKK-2 inhibitor blocks NF-kappa B-dependent gene expression in interleukin-1 beta-stimulated synovial fibroblasts. | Kishore, N., et al. 2003. J Biol Chem. 278: 32861-71. PMID: 12813046
- Hit-to-lead studies: the discovery of potent, orally active, thiophenecarboxamide IKK-2 inhibitors. | Baxter, A., et al. 2004. Bioorg Med Chem Lett. 14: 2817-22. PMID: 15125939
- BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways. | Yang, J., et al. 2006. Clin Cancer Res. 12: 950-60. PMID: 16467110
- The IKK inhibitor BMS-345541 affects multiple mitotic cell cycle transitions. | Blazkova, H., et al. 2007. Cell Cycle. 6: 2531-40. PMID: 17704647
- p65 activity and ZAP-70 status predict the sensitivity of chronic lymphocytic leukemia cells to the selective IkappaB kinase inhibitor BMS-345541. | López-Guerra, M., et al. 2009. Clin Cancer Res. 15: 2767-76. PMID: 19351760
- BMS-345541 sensitizes MCF-7 breast cancer cells to ionizing radiation by selective inhibition of homologous recombinational repair of DNA double-strand breaks. | Wu, L., et al. 2013. Radiat Res. 179: 160-70. PMID: 23259762
- IKK inhibition by BMS-345541 suppresses breast tumorigenesis and metastases by targeting GD2+ cancer stem cells. | Battula, VL., et al. 2017. Oncotarget. 8: 36936-36949. PMID: 28415808
- BMS‑345541 inhibits airway inflammation and epithelial‑mesenchymal transition in airway remodeling of asthmatic mice. | Zhu, X., et al. 2018. Int J Mol Med. 42: 1998-2008. PMID: 30015827
- Loss of PTEN induces lung fibrosis via alveolar epithelial cell senescence depending on NF-κB activation. | Tian, Y., et al. 2019. Aging Cell. 18: e12858. PMID: 30548445
Inhibitor of:
β-defensin 10, β-defensin 11, β-defensin 13, β-defensin 17, 1600012F09Rik, ANKRD29, C230055K05Rik, C2orf77, CARD 6, CCDC22, CRIM2, CTNNAL1, D14Ertd668e, EDARADD, EG665186, EOMES, EPCR, ephrin-B2, FOXC2, FOXP1, GABP-α, GM-CSFRα, Hepatocyte Specific Antigen, HHV-4 LMP-1, IκB-β, IκB-δ, IκB-γ, ICAP-1, ICEBERG, IFIT3, IFN-α14, IFN-α7, IFN-α8, IGFL3, IGFL4, IGIP, IKK alpha, IKK beta, IKK-i, IKKα, IKKγ, IL-13Rα2, IL-22R 1, IL-TIF, IRAK-1, IRF-6, IRS-4, LRRC2, LRRFIP2, LURAP1L, Ly-6C2, LYPD2, MIP-3α, Msx-2, NFKBIL2, NIK, Nlrp12, Olfr478, Olfr521, Olfr55, Olfr550, OTTMUSG00000011282, p105, p8, PDC-TREM, PLET1, Rae-1γ, RIG-I, Ripply2, RNF23, SASH (SAM and SH3 domain containing), SCGF, SPATA2, SPEC2, Spi-C, ST2, Syndecan-4, TARM1, TICAM-1, TLR6, TMEM214, TRAFD1, TREM-3, TREX-1, and TTP.Activator of:
ANKRD24, C1q, D630045J12Rik, IκB-α, IκB-γ, I830012O16Rik, IKIP, LRRFIP1, RSAD2, TACI, and TRIM48.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
BMS-345541, 1 mg | sc-221741 | 1 mg | $306.00 |